These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 32246814)

  • 1. Pre-analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients.
    Schneegans S; Lück L; Besler K; Bluhm L; Stadler JC; Staub J; Greinert R; Volkmer B; Kubista M; Gebhardt C; Sartori A; Irwin D; Serkkola E; Af Hällström T; Lianidou E; Sprenger-Haussels M; Hussong M; Mohr P; Schneider SW; Shaffer J; Pantel K; Wikman H
    Mol Oncol; 2020 May; 14(5):1001-1015. PubMed ID: 32246814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single tube liquid biopsy for advanced non-small cell lung cancer.
    de Wit S; Rossi E; Weber S; Tamminga M; Manicone M; Swennenhuis JF; Groothuis-Oudshoorn CGM; Vidotto R; Facchinetti A; Zeune LL; Schuuring E; Zamarchi R; Hiltermann TJN; Speicher MR; Heitzer E; Terstappen LWMM; Groen HJM
    Int J Cancer; 2019 Jun; 144(12):3127-3137. PubMed ID: 30536653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the liquid biopsy for the detection of BRAFV600E mutation in metastatic melanoma patients.
    Salvianti F; Massi D; De Giorgi V; Gori A; Pazzagli M; Pinzani P
    Cancer Biomark; 2019; 26(3):271-279. PubMed ID: 31524142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid Biopsy in Melanoma: Significance in Diagnostics, Prediction and Treatment Monitoring.
    Kamińska P; Buszka K; Zabel M; Nowicki M; Alix-Panabières C; Budna-Tukan J
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575876
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Mastoraki S; Strati A; Tzanikou E; Chimonidou M; Politaki E; Voutsina A; Psyrri A; Georgoulias V; Lianidou E
    Clin Cancer Res; 2018 Mar; 24(6):1500-1510. PubMed ID: 29284708
    [No Abstract]   [Full Text] [Related]  

  • 6. Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer.
    Vitale SR; Helmijr JA; Gerritsen M; Coban H; van Dessel LF; Beije N; van der Vlugt-Daane M; Vigneri P; Sieuwerts AM; Dits N; van Royen ME; Jenster G; Sleijfer S; Lolkema M; Martens JWM; Jansen MPHM
    BMC Cancer; 2021 Mar; 21(1):315. PubMed ID: 33761899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA.
    Onidani K; Shoji H; Kakizaki T; Yoshimoto S; Okaya S; Miura N; Sekikawa S; Furuta K; Lim CT; Shibahara T; Boku N; Kato K; Honda K
    Cancer Sci; 2019 Aug; 110(8):2590-2599. PubMed ID: 31169336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer.
    Rossi G; Mu Z; Rademaker AW; Austin LK; Strickland KS; Costa RLB; Nagy RJ; Zagonel V; Taxter TJ; Behdad A; Wehbe FH; Platanias LC; Gradishar WJ; Cristofanilli M
    Clin Cancer Res; 2018 Feb; 24(3):560-568. PubMed ID: 29180605
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer.
    Moon SM; Kim JH; Kim SK; Kim S; Kwon HJ; Bae JS; Lee S; Lee HS; Choi MY; Jeon BH; Jeong BH; Lee K; Kim HK; Kim J; Um SW
    Anticancer Res; 2020 Jun; 40(6):3435-3444. PubMed ID: 32487642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.
    Verma S; Moore MW; Ringler R; Ghosal A; Horvath K; Naef T; Anvari S; Cotter PD; Gunn S
    BMC Cancer; 2020 Oct; 20(1):945. PubMed ID: 33004033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the efficacy of an innovative diagnostic method for identifying 5 % variants in somatic ctDNA.
    Mareso C; Crosta L; De Vita MG; Cristofoli F; Tanzi B; Benedetti S; Bonetti G; Donofrio CA; Cominetti M; Riccio L; Fioravanti A; Generali D; Lucci Cordisco E; Chiurazzi P; Gatta V; Stuppia L; Cecchin S; Bertelli M; Marceddu G
    Gene; 2024 Nov; 928():148771. PubMed ID: 39032702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma.
    Bustamante P; Tsering T; Coblentz J; Mastromonaco C; Abdouh M; Fonseca C; Proença RP; Blanchard N; Dugé CL; Andujar RAS; Youhnovska E; Burnier MN; Callejo SA; Burnier JV
    J Exp Clin Cancer Res; 2021 Jun; 40(1):196. PubMed ID: 34134723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
    Fici P
    Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients.
    Huang SK; Hoon DS
    Mol Oncol; 2016 Mar; 10(3):450-63. PubMed ID: 26778792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Blood Collection Tubes from Three Different Manufacturers for the Collection of Cell-Free DNA for Liquid Biopsy Mutation Testing.
    Alidousty C; Brandes D; Heydt C; Wagener S; Wittersheim M; Schäfer SC; Holz B; Merkelbach-Bruse S; Büttner R; Fassunke J; Schultheis AM
    J Mol Diagn; 2017 Sep; 19(5):801-804. PubMed ID: 28732213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of ImproGene cfDNA blood collection tubes for mutation analysis in cancer patients.
    Zhang S; Zhou D; Li S; Bai Y; Huang B; Han J; Xu M; Wang S; Deng G
    Scand J Clin Lab Invest; 2022 Sep; 82(5):378-384. PubMed ID: 35861435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanoma.
    Sementsov M; Ott L; Kött J; Sartori A; Lusque A; Degenhardt S; Segier B; Heidrich I; Volkmer B; Greinert R; Mohr P; Simon R; Stadler JC; Irwin D; Koch C; Andreas A; Deitert B; Thewes V; Trumpp A; Schneeweiss A; Belloum Y; Peine S; Wikman H; Riethdorf S; Schneider SW; Gebhardt C; Pantel K; Keller L
    EMBO Mol Med; 2024 Jul; 16(7):1560-1578. PubMed ID: 38898234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer.
    Germano G; Mauri G; Siravegna G; Dive C; Pierce J; Di Nicolantonio F; D'Incalci M; Bardelli A; Siena S; Sartore-Bianchi A
    Clin Colorectal Cancer; 2018 Mar; 17(1):80-83. PubMed ID: 29195807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.